معرفی
Dr Dana Hutchinson is a Research Fellow at Monash University's Department of Drug Discovery Biology, specializing in G-protein coupled receptors (GPCRs) and their roles in glucose metabolism and diabetes treatment. Her work focuses on leveraging GPCR specificity to target metabolic pathways like AMP-activated kinase (AMPK) with reduced side effects. She has received the National Health and Medical Research Council Career Development Award (2009) and leads projects on biased agonism in GLP-1R, GIPR dimerization, and novel drug targets.
Her research explores ligand-directed stimulus bias in drugs like beta blockers, aiming to enhance cardio-protective effects. Collaborations span institutions like the Australian Research Council and Atrogi AB, with recent projects addressing obesity and heart failure through GPCR modulation. Key contributions include identifying adrenergic agonists (e.g., ATR-127) targeting skeletal muscle and brown adipose tissue. Over 80 publications highlight her expertise in pharmacology, metabolic disorders, and drug development.
- Grants: ARC-funded projects on GLP-1R/GIPR dimerization (2023–2026) and drug targets via GPCR dimers (2023).
- Recent Articles: Focus on incretin therapies, β-adrenergic agonist mechanisms, and mTORC2-mediated glucose pathways.
- Labs/Teams: Collaborates with teams like Summers Lab (drug characterization) and Cary/Wootten groups on obesity research.
